Free Trial
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Sunshine Biopharma logo
$1.44 +0.01 (+0.70%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.03 (+1.74%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Key Stats

Today's Range
$1.39
$1.47
50-Day Range
$1.22
$2.25
52-Week Range
$1.17
$14.00
Volume
46,204 shs
Average Volume
599,810 shs
Market Capitalization
$6.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

Sunshine Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

SBFM MarketRank™: 

Sunshine Biopharma scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sunshine Biopharma has received no research coverage in the past 90 days.

  • Read more about Sunshine Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sunshine Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    6.40% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 34.51%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sunshine Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sunshine Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.40% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 34.51%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sunshine Biopharma has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Sunshine Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

  • Percentage Held by Institutions

    41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sunshine Biopharma's insider trading history.
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBFM Stock News Headlines

Sunshine Biopharma launches Everolimus in Canada
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

SBFM Stock Analysis - Frequently Asked Questions

Sunshine Biopharma's stock was trading at $3.00 at the beginning of the year. Since then, SBFM stock has decreased by 52.0% and is now trading at $1.44.
View the best growth stocks for 2025 here
.

Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.44) EPS for the quarter. The business earned $8.90 million during the quarter. Sunshine Biopharma had a negative net margin of 12.82% and a negative trailing twelve-month return on equity of 17.89%.

Sunshine Biopharma shares reverse split on Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Top institutional investors of Sunshine Biopharma include Altium Capital Management LLC (1.86%). Insiders that own company stock include Camille Sebaaly and Steve N Slilaty.
View institutional ownership trends
.

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
5/29/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SBFM
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+941.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.51 million
Pretax Margin
-12.48%

Debt

Sales & Book Value

Annual Sales
$36.23 million
Price / Cash Flow
N/A
Book Value
$1,651.69 per share
Price / Book
0.00

Miscellaneous

Free Float
1,223,000
Market Cap
$6.56 million
Optionable
Not Optionable
Beta
1.35
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:SBFM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners